
MDGL
USDMadrigal Pharmaceuticals Inc. Common Stock
Reaalajas hind
Hinnagraafik
Põhinäitajad
Turunäitajad
Avatud
$488.030
Kõrge
$494.550
Madal
$477.000
Maht
0.76M
Ettevõtte fundamentaalnäitajad
Turukapitalisatsioon
11.1B
Tööstusharu
Biotehnoloogia
Riik
United States
Kauplemisstatistika
Keskmine maht
0.37M
Börs
NMS
Valuuta
USD
52 nädala vahemik
Seotud uudised
B of A Securities Upgrades Madrigal Pharmaceuticals to Neutral, Raises Price Target to $445
B of A Securities analyst Alexandria Hammond upgrades Madrigal Pharmaceuticals from Underperform to Neutral and raises the price target from $266 to $445.
Madrigal to Present New Data from the Company's MASH Program at AASLD's The Liver Meeting 2025
Two oral presentations to highlight biomarker, imaging and quality-of-life data from the open-label compensated MASH cirrhosis (F4c) arm of the Phase 3 MAESTRO-NAFLD-1 trial of RezdiffraPoster of distinction examines the
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
CONSHOHOCKEN, Pa., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated
Truist Securities Initiates Coverage On Madrigal Pharmaceuticals with Buy Rating, Announces Price Target of $580
Truist Securities analyst Srikripa Devarakonda initiates coverage on Madrigal Pharmaceuticals with a Buy rating and announces Price Target of $580.
Seotud aktsiad
PZC
PIMCO California Municipal Income Fund III Common Shares of Beneficial Interest
SAMG
Silvercrest Asset Management Group Inc.
STHO
Star Holdings Shares of Beneficial Interest
EDAP
EDAP TMS S.A. American Depositary Shares
LION
Lionsgate Studios Corp. Common Shares
Püsi kursis
Määrake hinnateavitused, hankige tehisintellekti analüüsi uuendusi ja reaalajas turuuudiseid.